A cancer treatment set to was approved by the U.S. Food and Drug Administration earlier this month. Hopefully it will give women diagnosed with HER2-low breast cancer extended survival rates.
The groundbreaking new drug, Enhertu, deleoped by AstraZeneca, was given approval for use in women with unresectable or metastatic HER2-low breast cancer.
So what should you know about this treatment?
What are the findings of Enhertu trials?
According to the New England Journal of Medicine Enhertu “resulted in significantly longer progression-free and overall survival than the physician’s choice of chemotherapy.”
researchers recruited 557 patients with metastatic breast cancer who had the HER2-low subtype. Two-thirds of the patients received Enhertu; the others were treated with their doctor’s preferred treatment.
The patients that received Enhertu, had tumor growth stopped for 10 month. Those who received chemotherapy, had tumor growth stop on average for five months. Enhertu patients survived for 23.9 months, while those that recieved chemotherapy survived 16.8 months.
New england Journal of medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2203690https://www.breastcancer.org/treatment/targeted-therapy/enhertu